Cyclopropyl dihydroquinoline sulfonamide compounds

    公开(公告)号:US11807634B2

    公开(公告)日:2023-11-07

    申请号:US17344939

    申请日:2021-06-10

    Applicant: AMGEN INC.

    CPC classification number: C07D413/12

    Abstract: The present invention provides a compound of Formula (I):






    an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular NaV1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

    Cyclobutyl dihydroquinoline sulfonamide compounds

    公开(公告)号:US12240839B2

    公开(公告)日:2025-03-04

    申请号:US17633151

    申请日:2021-06-10

    Applicant: AMGEN INC.

    Abstract: The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

Patent Agency Ranking